Omics technologies in personalized combination therapy for cardiovascular diseases: challenges and opportunities.

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-25 DOI:10.2217/pme-2021-0087
Saradindu Banerjee, Navya Prabhu Basrur, Padmalatha S Rai
{"title":"Omics technologies in personalized combination therapy for cardiovascular diseases: challenges and opportunities.","authors":"Saradindu Banerjee,&nbsp;Navya Prabhu Basrur,&nbsp;Padmalatha S Rai","doi":"10.2217/pme-2021-0087","DOIUrl":null,"url":null,"abstract":"<p><p>The primary purpose of 'omics' technologies is to understand the intricacy of genomics, proteomics, metabolomics and other molecular mechanisms to reveal the complex traits of human diseases. The significant use of omics technologies and their applications in medicine gear up the study of the pathogenesis of several disorders. The detection of biomarkers in the early onset of diseases is challenging; still, omics can discover novel molecular mechanisms and biomarkers. In this review, the different types of omics and their technologies are explicated and aimed to provide their emerging applications in cardiovascular precision medicine. These technologies significantly impact optimizing medical treatment for individuals to reach a higher level in precision medicine.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"595-611"},"PeriodicalIF":1.7000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2021-0087","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 3

Abstract

The primary purpose of 'omics' technologies is to understand the intricacy of genomics, proteomics, metabolomics and other molecular mechanisms to reveal the complex traits of human diseases. The significant use of omics technologies and their applications in medicine gear up the study of the pathogenesis of several disorders. The detection of biomarkers in the early onset of diseases is challenging; still, omics can discover novel molecular mechanisms and biomarkers. In this review, the different types of omics and their technologies are explicated and aimed to provide their emerging applications in cardiovascular precision medicine. These technologies significantly impact optimizing medical treatment for individuals to reach a higher level in precision medicine.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
组学技术在心血管疾病个性化联合治疗中的应用:挑战与机遇。
“组学”技术的主要目的是了解基因组学、蛋白质组学、代谢组学和其他分子机制的复杂性,以揭示人类疾病的复杂特征。组学技术的大量使用及其在医学上的应用加快了对几种疾病发病机制的研究。在疾病早期检测生物标志物具有挑战性;然而,组学可以发现新的分子机制和生物标志物。本文综述了不同类型的组学及其技术,旨在为其在心血管精准医学中的应用提供参考。这些技术显著影响优化医疗个人达到更高水平的精准医疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Personalized medicine
Personalized medicine 医学-药学
CiteScore
3.30
自引率
4.30%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
期刊最新文献
Challenges and opportunities in building a health economic framework for personalized medicine in oncology. Developing and validating noninvasive prenatal testing for de novo autosomal dominant monogenic diseases in Vietnam. Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems. Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1